Drug Approval | February 14, 2026
FDA nod to Acrotech's new eczema treatment
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
The surge has been driven largely by COCO stores, with 755 COCO and 165 FOFO outlets added this fiscal year
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Garijo will be the first woman to lead Sanofi in its history
Subscribe To Our Newsletter & Stay Updated
